“Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

“Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents

Published:2009-01-10 Issue:6 Volume:27 Page:552-556
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Penel Nicolas,Isambert Nicolas,Leblond Pierre,Ferte Charles,Duhamel Alain,Bonneterre Jacques

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-008-9213-5.pdf

Reference13 articles.

1. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA, Task Force on Methodology for the Development of Innovative Cancer Therapies (2008) Eur J Cancer 44:19–24. doi: 10.1016/j.ejca.2007.07.034

2. Morabito A, Di Maio E, Normanno N, Perrone F (2006) Methodology of clinical trials with new molecular-targeted agents: where do we stand? Ann Oncol 17(S7):vii128–vii131. doi: 10.1093/annonc/mdl965

3. Ratain MJ, Mick R, Schilsky R et al (1993) Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637–1643. doi: 10.1093/jnci/85.20.1637

4. Simon R, Friedlin B, Rubinstein LV, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–1147. doi: 10.1093/jnci/89.15.1138

5. Verweij J (2008) "No risk, no fun": challenges for the oncology phase I clinical trial time-performance. Eur J Cancer 44:2600–2607. doi: 10.1016/j.ejca.2008.07.043

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety and feasibility of transcranial direct current stimulation for patients with chronic severe traumatic brain injury in Japan, a phase I study;Brain Disorders;2024-03

2. Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial;Investigational New Drugs;2020-03-12

3. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial;The Lancet Oncology;2019-08

4. First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors;Molecular Cancer Therapeutics;2019-01-24

5. Changing Landscape of Early Phase Clinical Trials;Novel Designs of Early Phase Trials for Cancer Therapeutics;2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3